Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
103.87
-4.10 (-3.80%)
Feb 5, 2026, 4:00 PM EST - Market closed
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $51.30M in the quarter ending September 30, 2025, with 54.28% growth. This brings the company's revenue in the last twelve months to $174.33M, up 54.92% year-over-year. In the year 2024, Rhythm Pharmaceuticals had annual revenue of $130.13M with 68.06% growth.
Revenue (ttm)
$174.33M
Revenue Growth
+54.92%
P/S Ratio
37.93
Revenue / Employee
$616,021
Employees
283
Market Cap
6.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.78B |
| Caris Life Sciences | 649.06M |
| Mirum Pharmaceuticals | 471.79M |
| Krystal Biotech | 373.16M |
| Cytokinetics | 87.21M |
| Kymera Therapeutics | 43.74M |
| Praxis Precision Medicines | 7.46M |
| ABIVAX Société Anonyme | 6.23M |
RYTM News
- 1 day ago - Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit - GlobeNewsWire
- 4 weeks ago - Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - GlobeNewsWire
- 2 months ago - Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster - Seeking Alpha
- 2 months ago - Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript - Seeking Alpha
- 2 months ago - Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise - Benzinga
- 2 months ago - Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome - GlobeNewsWire
- 2 months ago - Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome - GlobeNewsWire
- 2 months ago - Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress - Seeking Alpha